Viking Therapeutics ( (VKTX) ) has risen by 7.76%. Read on to learn why.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Viking Therapeutics has seen a notable 7.76% increase in its stock price over the past week, driven by positive developments in its clinical pipeline and strong analyst endorsements. The company has made significant progress in its VK2735 program, advancing into Phase III trials, which target obesity and type 2 diabetes. This advancement, along with promising Phase II results showing substantial weight loss, has bolstered investor confidence.
Analysts have been optimistic about Viking Therapeutics, with several reiterating Buy ratings and setting high price targets. Notably, Jefferies and Cantor Fitzgerald have maintained their Buy ratings with targets of $101 and $104, respectively. The consensus among analysts is a Strong Buy, with an average price target suggesting a significant upside from current levels. These endorsements reflect the market’s positive outlook on the company’s strategic initiatives and clinical advancements.
Despite the positive momentum, Viking Therapeutics faces financial challenges, including increased net losses and rising R&D expenses. The company reported a net loss of $65.6 million in Q2 2025, primarily due to higher expenses associated with its clinical programs. However, with a robust cash position of $808 million, Viking Therapeutics is well-equipped to continue its innovative work and address these financial hurdles, maintaining a balanced approach to growth and investment.